CA2703340A1 - Systeme pour traiter des defauts de l'os et/ou du cartilage et procedes d'utilisation de celui-ci - Google Patents
Systeme pour traiter des defauts de l'os et/ou du cartilage et procedes d'utilisation de celui-ci Download PDFInfo
- Publication number
- CA2703340A1 CA2703340A1 CA2703340A CA2703340A CA2703340A1 CA 2703340 A1 CA2703340 A1 CA 2703340A1 CA 2703340 A CA2703340 A CA 2703340A CA 2703340 A CA2703340 A CA 2703340A CA 2703340 A1 CA2703340 A1 CA 2703340A1
- Authority
- CA
- Canada
- Prior art keywords
- bone
- subject
- bmp
- defect
- flow rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000007547 defect Effects 0.000 title claims abstract description 173
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 137
- 238000000034 method Methods 0.000 title claims abstract description 120
- 210000000845 cartilage Anatomy 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 claims description 95
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 78
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 78
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 78
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 53
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 53
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 52
- 108010035532 Collagen Proteins 0.000 claims description 35
- 102000008186 Collagen Human genes 0.000 claims description 35
- 229920001436 collagen Polymers 0.000 claims description 34
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 24
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 24
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 22
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 19
- 230000008439 repair process Effects 0.000 claims description 14
- 230000002459 sustained effect Effects 0.000 claims description 14
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 13
- 206010049088 Osteopenia Diseases 0.000 claims description 13
- 208000001132 Osteoporosis Diseases 0.000 claims description 11
- 210000000130 stem cell Anatomy 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 8
- 229920002230 Pectic acid Polymers 0.000 claims description 6
- 238000011961 computed axial tomography Methods 0.000 claims description 6
- 238000012423 maintenance Methods 0.000 claims description 6
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 6
- 239000010318 polygalacturonic acid Substances 0.000 claims description 6
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003349 gelling agent Substances 0.000 claims description 5
- 239000007943 implant Substances 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 208000030016 Avascular necrosis Diseases 0.000 claims description 4
- 102000012422 Collagen Type I Human genes 0.000 claims description 4
- 108010022452 Collagen Type I Proteins 0.000 claims description 4
- 206010031264 Osteonecrosis Diseases 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000037182 bone density Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229940096422 collagen type i Drugs 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 102000001187 Collagen Type III Human genes 0.000 claims description 3
- 108010069502 Collagen Type III Proteins 0.000 claims description 3
- 229910000861 Mg alloy Inorganic materials 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 3
- 238000002600 positron emission tomography Methods 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002513 implantation Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 40
- 241000282472 Canis lupus familiaris Species 0.000 description 24
- 230000012010 growth Effects 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 19
- 230000003247 decreasing effect Effects 0.000 description 16
- 230000035876 healing Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 11
- 230000011164 ossification Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 210000003141 lower extremity Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 210000000623 ulna Anatomy 0.000 description 6
- 102000005593 Endopeptidases Human genes 0.000 description 5
- 108010059378 Endopeptidases Proteins 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 230000000278 osteoconductive effect Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 3
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000007327 Protamines Human genes 0.000 description 3
- 108010007568 Protamines Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000008468 bone growth Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- -1 barbiturates Substances 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000002138 osteoinductive effect Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000276 sedentary effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 108010030102 COLLOSS E Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 206010066386 Impacted fracture Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241001447056 Uristes Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000003848 cartilage regeneration Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000045896 human BMP2 Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws or setting implements
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/70—Spinal positioners or stabilisers, e.g. stabilisers comprising fluid filler in an implant
- A61B17/7001—Screws or hooks combined with longitudinal elements which do not contact vertebrae
- A61B17/7002—Longitudinal elements, e.g. rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws or setting implements
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/84—Fasteners therefor or fasteners being internal fixation devices
- A61B17/86—Pins or screws or threaded wires; nuts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/32—Joints for the hip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
- A61F2/4455—Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/02—Bones
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21407P | 2007-10-24 | 2007-10-24 | |
| US61/000,214 | 2007-10-24 | ||
| PCT/IB2008/002826 WO2009053820A1 (fr) | 2007-10-24 | 2008-10-17 | Système pour traiter des défauts de l'os et/ou du cartilage et procédés d'utilisation de celui-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2703340A1 true CA2703340A1 (fr) | 2009-04-30 |
Family
ID=40433599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2703340A Abandoned CA2703340A1 (fr) | 2007-10-24 | 2008-10-17 | Systeme pour traiter des defauts de l'os et/ou du cartilage et procedes d'utilisation de celui-ci |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU2008315663A1 (fr) |
| CA (1) | CA2703340A1 (fr) |
| IL (1) | IL205250A0 (fr) |
| WO (1) | WO2009053820A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734459B1 (en) | 2013-01-17 | 2014-05-27 | Abdulrazzaq Alobaid | Device and method to prevent extravasation of bone cement used in balloon kyphoplasty |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4619989A (en) * | 1981-05-05 | 1986-10-28 | The Regents Of The University Of Cal. | Bone morphogenetic protein composition |
| US5122114A (en) * | 1991-02-01 | 1992-06-16 | Board Of Regents, University Of Texas System | Method of using intramedullary catheter |
| US6387098B1 (en) * | 1999-10-21 | 2002-05-14 | Peter Alexander Cole | Intramedullary catheter nail apparatus and method |
| IL142480A0 (en) * | 2001-04-05 | 2002-03-10 | Univ Ben Gurion | Tissue growth stimulating system |
| CN101370634A (zh) * | 2005-02-16 | 2009-02-18 | 亚历山大·R·瓦卡若 | 供植入与药物传递的再吸收中空装置 |
| US20070179609A1 (en) * | 2006-01-27 | 2007-08-02 | Medicinelodge, Inc. | Therapeutic agent eluding implant with percutaneous supply |
-
2008
- 2008-10-17 CA CA2703340A patent/CA2703340A1/fr not_active Abandoned
- 2008-10-17 AU AU2008315663A patent/AU2008315663A1/en not_active Abandoned
- 2008-10-17 WO PCT/IB2008/002826 patent/WO2009053820A1/fr not_active Ceased
-
2010
- 2010-04-22 IL IL205250A patent/IL205250A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009053820A4 (fr) | 2009-07-02 |
| IL205250A0 (en) | 2010-12-30 |
| WO2009053820A1 (fr) | 2009-04-30 |
| AU2008315663A1 (en) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022203758B2 (en) | Compositions and methods to promote bone formation | |
| US20080051800A1 (en) | Method and device for reducing susceptibility to fractures in vertebral bodies | |
| KR102751476B1 (ko) | 자가 골 이식편 대체재 | |
| WO2006049797A2 (fr) | Implant rachidien de prevention des fractures pour os osteoporotique non fracture | |
| JP2004503596A (ja) | トロンビンペプチド誘導体による骨成長の刺激 | |
| TW200307559A (en) | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins | |
| Kimura et al. | Gelatin hydrogel as a carrier of recombinant human fibroblast growth factor-2 during rat mandibular distraction | |
| Cunningham et al. | Osseointegration of autograft versus osteogenic protein–1 in posterolateral spinal arthrodesis: emphasis on the comparative mechanisms of bone induction | |
| TW200800250A (en) | Protein formulation for promoting hard tissue formation | |
| Tanjaya et al. | The effects of systemic therapy of PEGylated NEL-like protein 1 (NELL-1) on fracture healing in mice | |
| CA2703340A1 (fr) | Systeme pour traiter des defauts de l'os et/ou du cartilage et procedes d'utilisation de celui-ci | |
| AU2008247320B2 (en) | A method for treating inflammation and controlled-release material capable of providing same | |
| Zachos et al. | Growth factors and their potential therapeutic applications for healing of musculoskeletal and other connective tissues | |
| Tsuzuki et al. | Effect of biodegradable gelatin β-tri calcium phosphate sponges containing mesenchymal stem cells and bone morphogenetic protein-2 on equine bone defect | |
| US20210169977A1 (en) | Compositions of Transforming Growth Factor-Beta Type III Receptor and Uses for Ossification | |
| Kavaseri | Cell therapy and mechanical stimulation to enhance bone defect healing | |
| JP2024537024A (ja) | 骨形態形成タンパク質及び受容体のｍＲＮＡ誘導発現及びこれに関する方法 | |
| Panos | Immunomodulation to Improve the Clinical Performance of Bone Morphogenetic Protein 2 | |
| Lullo | Source and Carrier Effect on the Bioactivity of BMP Bio-implants | |
| Haas et al. | Biotechnology in Trauma | |
| Mardirosian | Effects of Bone Morphogenetic Protein (rhBMP-2) and Platelet Derived Growth Factor (rhPDGF-BB) on Ectopic Bone Formation In Rats | |
| HK40019925B (zh) | 自体骨移植物替代物 | |
| Lee | A Pilot Study to Compare the Activity of Different Bone Morphogenetic Protein Bioimplants In Vivo | |
| Koh et al. | Research Article BMP6-Engineered MSCs Induce Vertebral Bone Repair in a Pig Model: A Pilot Study | |
| Chien | Cells in Orthopedic Surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |